Trulieve Makes History With First NYSE Cannabis Listing
Trulieve, the largest U.S. cannabis operator, will list its subordinate voting shares on the New York Stock Exchange on June 10, 2026, under the ticker 'TRLV,' marking the first cannabis company to trade on a major U.S. exchange. The move follows the Trump administration’s April reclassification of medical marijuana to Schedule III, which enabled the company’s restructuring to meet NYSE listing requirements.
Trulieve, a leading U.S. cannabis company, announced its subordinate voting shares will begin trading on the New York Stock Exchange (NYSE) on June 10, 2026, under the ticker symbol 'TRLV.' This marks the first time a cannabis company has listed on a major U.S. exchange, following the Trump administration’s April decision to reclassify medical marijuana to Schedule III under federal drug laws. The uplisting was made possible after Trulieve restructured its operations to separate medical and adult-use cannabis markets. The company’s consolidated operations now include 206 medical marijuana dispensaries and 3.5 million square feet of DEA-registered production capacity. Trulieve’s shares will continue trading on the Canadian Securities Exchange (symbol 'TRUL') and OTCQX (symbol 'TCNNF') until market close on June 9, with no action required from existing shareholders. Kim Rivers, Trulieve’s founder and CEO, stated the uplisting would expand shareholder access and increase liquidity, while highlighting the Trump administration’s policy change as a key enabler. The company also emphasized its focus on medical cannabis access, citing expansion plans in Georgia and Texas as growth catalysts. Industry analysts noted the listing reflects Wall Street’s cautious but growing interest in cannabis, contingent on regulatory clarity. Adam Stettner of FundCanna called the move a milestone but stressed it resulted from Trulieve’s financial restructuring rather than broad market acceptance. He added that the upcoming DEA hearing on June 29 could further shape investor confidence if adult-use cannabis is also reclassified. Trulieve’s NYSE listing follows a strategic deconsolidation to align with exchange requirements, ensuring compliance with institutional investment standards. The company’s cash generation and medical-focused operations position it as a leader in the evolving cannabis market, though analysts warn selective institutional engagement remains limited until broader regulatory reforms are finalized.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.